WO1991002529A3 - Product and method for killing abnormal vertebrate cells - Google Patents

Product and method for killing abnormal vertebrate cells Download PDF

Info

Publication number
WO1991002529A3
WO1991002529A3 PCT/US1990/004469 US9004469W WO9102529A3 WO 1991002529 A3 WO1991002529 A3 WO 1991002529A3 US 9004469 W US9004469 W US 9004469W WO 9102529 A3 WO9102529 A3 WO 9102529A3
Authority
WO
WIPO (PCT)
Prior art keywords
cells
product
diaminoacridine
proflavine
concentrations
Prior art date
Application number
PCT/US1990/004469
Other languages
French (fr)
Other versions
WO1991002529A2 (en
Inventor
John Bennett Kizer
Original Assignee
John Bennett Kizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by John Bennett Kizer filed Critical John Bennett Kizer
Publication of WO1991002529A2 publication Critical patent/WO1991002529A2/en
Publication of WO1991002529A3 publication Critical patent/WO1991002529A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines

Abstract

A product and method for killing undesirable abnormal tissue or blood cells while saving normal tissues or cells. A diaminoacridine compound, proflavine in the preferred embodiment, lyses abnormal cells over a period of 6 hours to 2 days when those cells are exposed to diaminoacridine over that period of time at concentrations of at least 1 mg/kg of body weight. Concentrations of diaminoacridines of at least 15 mg/kg of body weight are harmless to humans beyond causing a transitory hypersensitivity to sun light. Specifically, proflavine is a useful treatment for cancer and, in theory, should be useful against AIDS, rheumatoid arthritis and psoriasis.
PCT/US1990/004469 1989-08-14 1990-08-09 Product and method for killing abnormal vertebrate cells WO1991002529A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US39351489A 1989-08-14 1989-08-14
US393,514 1989-08-14

Publications (2)

Publication Number Publication Date
WO1991002529A2 WO1991002529A2 (en) 1991-03-07
WO1991002529A3 true WO1991002529A3 (en) 1991-04-04

Family

ID=23554997

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1990/004469 WO1991002529A2 (en) 1989-08-14 1990-08-09 Product and method for killing abnormal vertebrate cells

Country Status (1)

Country Link
WO (1) WO1991002529A2 (en)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2704856B1 (en) * 1993-05-04 1995-08-04 Pf Medicament New derivatives of 3-dimethylamino acridine.
GB9321558D0 (en) * 1993-10-19 1993-12-08 Radopath Ltd Anti-viral agents
GB2319474A (en) * 1993-10-19 1998-05-27 Radopath Ltd Anti-viral agents
FR2711527A1 (en) * 1993-10-22 1995-05-05 Richard Laboratoire M Use of acriflavine as an anti-HIV agent
US6221882B1 (en) * 1997-07-03 2001-04-24 University Of Iowa Research Foundation Methods for inhibiting immunostimulatory DNA associated responses
DE19731238A1 (en) * 1997-07-21 1999-01-28 Zimmer Peter Use of aminoacridines for the treatment of solid tumors, metastases and lymphomas
US9044523B2 (en) 2000-06-15 2015-06-02 Terumo Bct, Inc. Reduction of contaminants in blood and blood products using photosensitizers and peak wavelengths of light
JPWO2006095897A1 (en) * 2005-03-08 2008-08-21 武田薬品工業株式会社 Screening method
RU2349311C1 (en) * 2007-08-02 2009-03-20 Михаил Владимирович Кутушов Application of naphthalene derivative as oncological disease treatment medicine
CN108853102B (en) * 2017-05-15 2021-04-09 北京大学 Condensed acridine derivatives acting on Dectin-1 and uses thereof
CN112336864A (en) * 2019-08-08 2021-02-09 厦门大学 Application of proflavine in lung cancer treatment
WO2023116397A1 (en) * 2021-12-25 2023-06-29 珞达生物医药(苏州)有限公司 Innate immune-activating drug and use thereof
WO2023242104A1 (en) 2022-06-13 2023-12-21 KHR Biotec GmbH Diaminoacridine derivatives as inhibitors of ras

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
Arzneimittelforschung, Vol. 25, No. 10, 1975, H. OSSWALD: "Potentiated Chemotherapeutic Activity of 3,6-Diamino-10-Methyl-Acridinium by Combination with Glycine or DL-alpha-Alanine on the Ehrlich Carcinoma", pages 1608-1609 see page 1609, left-hand column, line 31 - right-hand column, line 32 *
Cancer Chemother. Pharmacol., Vol. 1, No. 1, 1978, Springer Verlag, G. MATHE et al.: "New Cancer Chemotherapy Drugs in Europe", pages 5-13 see page 9, right-hand column, lines 50-54 *
Eur. J. Cancer, Vol. 16, No. 9, 1980, Pergamon Press Ltd, (GB), I.G.C. ROBERTSON et al.: "Inhibition of T4 Bacteriophage Yield by 9-Anilino-Acridines; Comparison with in Vivo Anti-Tumour Activity", pages 1133-1140 see page 1134, right-hand column, lines 7-14; page 1136, table I, Compounds 25-38 *
J. Inst. Chemists (India), Vol. 60, No. 2, March 1988, N.G. CHAKRABORTY et al.: "Chemical Modification of Tumor Cell Surface with Different Acridine Dyes", pages 51-52 see page 51, lines 9-20 *
J. Med. Chem. Vol. 30, No. 4, 1987, American Chemical Society, W.A. DENNY et al.: "Potential Antitumor Agents. 49. 5-Substituted Derivatives of N-(2-(Dimethylamino) Ethtyl) -9-Aminoacridine-4-Carboxamide with in Vivo Solid-Tumor Activity", pages 658-663 see table 1, Compound 14 *

Also Published As

Publication number Publication date
WO1991002529A2 (en) 1991-03-07

Similar Documents

Publication Publication Date Title
WO1991002529A3 (en) Product and method for killing abnormal vertebrate cells
AU5432596A (en) Tricyclic compounds useful in the treatment of cell prolifer ative disorders
CS141387A2 (en) Microbicide
AU576365B2 (en) Collagen and or fibrinogen as carrier of drugs for their introduction into cellular lesion areas
CA2158475A1 (en) Composition and method for reducing toxicity of biologically-active factors
CA2017705A1 (en) Human heart valve replacement with porcine pulmonary valve
CA2029420A1 (en) Pharmaceutical compositions and methods for inhibition of maillard's reaction
AU4032989A (en) Method and compositions for the treatment and prevention of septic shock
AU5046693A (en) Use of purified surface modifiers to prevent particle aggregation during sterilization
AU8138687A (en) Agents for combating pests and plant treatment agents
MY106528A (en) Method of treating impotence.
PL310474A1 (en) Application of rilusole in treating neuro-aids diseases
MY102648A (en) Pharmacological / cosmetic preparation
AU5317390A (en) Concentrated aqueous solution of glutaraldehyde and 1,2-benzisothiazolin-3-one
CA2060474A1 (en) Pharmaceutical use
GB2210789A (en) Topical application for skin care
AU669946B2 (en) Lanolin/lanolin acid ester skin treatment composition
AU3511589A (en) Method and apparatus for treating fresh fruit and the like to prevent and retard the growth of fungus
CA2150714A1 (en) Syndecan stimulation of cellular differentiation
AU1329895A (en) Metallic implant and process for treating a metallic implant
CA2129043A1 (en) Use of 3,5-diamino-6-(2,3-dichlorophenyl)-1,2,4-triazine for the treatment of pain and oedema
EP0357646A4 (en) Treatment of aged skin with oral 13-cis-retinoic acid
AU7609094A (en) Treatment and prophylaxis of diseases caused by parasites or bacteria
RU93003584A (en) METHOD FOR TREATING SYNDROME OF POLYCYSTIC OVARY
CA2394365A1 (en) Use of a semicarbazone plant growth regulator for crop yield enhancements

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): CA JP

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH DE DK ES FR GB IT LU NL SE

AK Designated states

Kind code of ref document: A3

Designated state(s): CA JP

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH DE DK ES FR GB IT LU NL SE

NENP Non-entry into the national phase in:

Ref country code: CA